Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers
Our study establishes the potential of Aurora A inhibition to sensitize HPV-positive tumors to ICIs, specifically anti-CTLA-4 treatment. This combination strategy resulted in enhanced antitumor efficacy, driven by systemic and intratumoral increases in CD8 T-cell responses and reduced immunosuppressive cell populations, specifically MDSCs. These findings offer insights into the synergistic effects of Aurora A inhibition and ICIs and argue for further investigation and optimization of this combination approach in HPV-driven cancers.
Authors
- Madison P. O’Hara (ORCID: https://orcid.org/0009-0009-2435-3410)
- Soma Ghosh (ORCID: https://orcid.org/0000-0002-6729-4838)
- Faye M. Johnson (ORCID: https://orcid.org/0000-0002-2862-4160)
- Laçin Yapindi (ORCID: https://orcid.org/0000-0002-9429-7583)
- Pragya Sinha (ORCID: https://orcid.org/0009-0008-2492-6656)
- Tuhina Mazumdar (ORCID: https://orcid.org/0000-0001-8359-8404)
- K. Jagannadha Sastry (ORCID: https://orcid.org/0000-0002-6987-4422)
Institutions
- Austin College (US)
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas at Austin (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-009316
- Citations
- 8
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- University of Texas Health Science Center at Houston
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston
- Center for Information Technology
- NIH Clinical Center